AMSBIO Announces US Office
AMSBIO has announced, as of 31st March 2011, the opening of a new North American subsidiary company - AMSBIO LLC.
After successfully selling innovative life science technologies, biotools and services directly to North American researchers, the new office will be a fully integrated entity supporting the AMSBIO product line with a dedicated sales and service facility in Orange County, California.
Commenting on this strategic move, Alex Sim (President, AMSBIO) said 'The US is the single largest market for our stem cell and regenerative medicine, lentivirus as well as tissue derived products and our North American customer base has been growing strongly over recent years'. He added 'In addition to providing local service and support for our US customers the new facilities will be able to offer next day delivery from a comprehensive inventory of popular products.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Medicon Valley Academy and Norgenta North German Life Science Agency agree on cooperation in two projects
ThromboGenics Announces License Agreement with Bharat Biotech for Novel Thrombolytic Agent

Diamond ring architecture of a protein complex
Taurine deficiency in sperm causes male infertility
Researchers from BGU have generated a promising drug candidate for the treatment of Psoriasis
Novartis begins shipment of Fluvirin seasonal influenza vaccine for the U.S. market ahead of schedule - Providing 30 million doses of Fluvirin vaccine in the U.S., to support the annual seasonal influenza vaccination campaign

Giant Viruses Infect Deadly Parasite - New unusual giant virus discovered in wastewater treatment plant
Active wound healing can accelerate tumour formation

SUANFARMA announces a collaboration with Reyoung Pharmaceutical - The main objective of the collaboration is to introduce generic pharmaceutical ingredients to the market for the treatment of infectious diseases
